Effects of Intranasal Oxytocin and Vasopressin on Social Behavior

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01296269
Recruitment Status : Unknown
Verified April 2011 by Hadassah Medical Organization.
Recruitment status was:  Recruiting
First Posted : February 15, 2011
Last Update Posted : April 8, 2011
Hebrew University of Jerusalem
Information provided by:
Hadassah Medical Organization

February 3, 2011
February 15, 2011
April 8, 2011
April 2011
May 2012   (Final data collection date for primary outcome measure)
allocations of monetary units [ Time Frame: approximately 45 minutes after intranasal administration of vasopressin, oxytocin, or placebo ]
Participants will make decisions regarding the allocation of monetary units between themselves and other participants. We will measure the quantity of monetary units kept for themselves vs. given to other participants
Same as current
Complete list of historical versions of study NCT01296269 on Archive Site
mood as measured via the visual analog scale [ Time Frame: approximately one hour and fifteen minutes after administration of oxytocin, vasopressin or placebo ]
Same as current
Not Provided
Not Provided
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior
Effects of Intranasal Oxytocin and Vasopressin on Social Behavior in Healthy Controls
The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and altruism in a healthy population of student controls.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Basic Science
  • Drug: Oxytocin
    one-time intranasal administration, 24 International Units, 5 puffs for each nostril
    Other Name: syntocinon
  • Drug: Arginine Vasopressin
    one-time intranasal administration, 20 International Units, 5 puffs in each nostril
  • Drug: placebo
    contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
  • Experimental: Vasopressin
    vasopressin condition
    Intervention: Drug: Arginine Vasopressin
  • Experimental: oxytocin
    oxytocin condition (syntocinon)
    Intervention: Drug: Oxytocin
  • Placebo Comparator: placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
Not Provided
May 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy controls

Exclusion Criteria:

  • Past or present psychiatric, neurological, endocrinological or severe chronic medical illness.
  • Use of medications or drugs that would interfere with study results. This includes steroids, medications for psychiatric symptoms like anxiety or depression, stimulants, and medications for high blood pressure. Participants will be asked to tell the investigators of any medications or drugs that they are taking. The investigators will consider the drug interactions with oxytocin and vasopressin prior to study, and participants will not be able to participate in the study if the drug interactions could be dangerous.
  • history of drug or alcohol addiction
  • Pregnancy or Nursing Status: Because of the risk to an unborn fetus or infant, women who are pregnant or nursing are excluded from this protocol. All females will have a pregnancy test performed no more than 24 hours before each drug administration and will not be able to participate if the pregnancy test is positive.
Sexes Eligible for Study: All
18 Years to 35 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
David Mankuta MD, Hadassah Ein-Kerem - obstetrics and gynecology
Hadassah Medical Organization
Hebrew University of Jerusalem
Principal Investigator: David Mankuta, MD Hadassah University Medical Organization
Hadassah Medical Organization
April 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP